LCTX Lineage Cell Therapeutics
- 1.000
- +0.011+1.13%
- 1.010
- +0.010+1.00%
Lineage Cell Therapeutics News
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics | DEFA14A: Others
Lineage Cell Therapeutics | DEF 14A: Definitive information statements
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics | DEFA14A: Others
Lineage Cell Therapeutics | DEF 14A: Definitive information statements
Lineage Cell Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | 8-K: Current report
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Analysis
Price Target
No Data
